Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Methoxsalen solution - Therakos

Drug Profile

Methoxsalen solution - Therakos

Alternative Names: Methoxsalen sterile solution - Therakos; UVADEX

Latest Information Update: 20 Apr 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Therakos
  • Developer Mallinckrodt Inc.; Therakos
  • Class Antineoplastics; Antipsoriatics; Coumarins; Psoralens; Small molecules
  • Mechanism of Action DNA cross linking agents; Photosensitisers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Cutaneous T-cell lymphoma
  • Registered Graft-versus-host disease

Most Recent Events

  • 30 Dec 2022 Mallinckrodt Pharmaceuticals has patent protection for Methoxsalen solution in USA and other countries
  • 30 Dec 2022 Mallinckrodt Pharmaceuticals has patents pending for Methoxsalen solution in USA
  • 07 Dec 2022 No development reported - Phase-III for Graft-versus-host disease (In adolescents, In children, In infants, In adults) in Germany, France (Extracorporeal) (NCT02524847)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top